For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Pfizer Inc. sued Metsera Inc. and rival drugmaker Novo Nordisk A/S to block the Danish company’s rival bid for the obesity ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...

Novo Nordisk's late bid to hijack Pfizer's takeover of US obesity biotech Metsera marks an aggressive shift from the Danish ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales growth for its blockbuster obesity drug Wegovy, Doustdar has already ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo said its bid, which is worth $1.6 billion more than Pfizer's initial offer for the obesity drug specialist, would ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...